RMTI

Rockwell Medical Inc. (RMTI) | Rumor.io

Rockwell Medical

RMTI

Attention (50-day avg)0%

Attention rank (50-day avg)#3,069

Bullish sentiment (50-day avg)92%

Price to earnings ratio-5.73

Market capitalization34.8M

Earnings per share-1.32

Dividend yield (TTM)—

Revenue (annual)69.3M

Net income (annual)-5.3M

Social

What share of all stock conversation is about RMTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Aug 13

Rockwell Medical, Inc. (RMTI) reported solid earnings, maintaining guidance for 2026 with $100 million+ revenue and 30% profit margins, with a new medical device opportunity in the works.
The company showed encouraging signs in its Q2 2026 earnings, with top-line growth, improved gross margins, and positive cash flow, but second-half execution remains critical.
RMTI's Q2 2026 results included a 11% increase in net sales to $17.8M, a 30% increase in gross profit to $3.2M, and a 18% gross margin, with the company reiterating its 2026 annual guidance.

Generated by AI

Sentiment

Of the messages about RMTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +50	85.71% -14.29	93.29% +13.33
Bearish	0%	0% -50	14.29% +14.29	6.71% -13.33

Bullish· Jan 20

Rockwell Medical, Inc. (RMTI) reported preliminary Q4 revenue of $18.6M, beating estimates, with a gross margin of 22% and positive operating cash flow for the second time in 2025.
The company's financial report has led to a significant price surge, with some analysts predicting a 198.80% change from the last price of $1.26, with a target price of $3.75.
RMTI's turnaround is in full effect, with the stock experiencing a 45% premarket gain, and a high buzz around the stock, with potential for dynamic trading ahead.

Bearish· Nov 12

$RMTI is facing a significant revenue decline due to Davita's reduced purchases, which could drop by 31-38 million next year.
The company's gross profit margin is expected to decline by up to 20% year-over-year, which could negatively impact the stock price.
Rockwell Medical's new contracts and pricing increases may not be enough to offset the revenue decline, leading to a prolonged bearish trend.

Generated by AI

Topics

Of the messages about RMTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	33.33%	72.22%	35.07%
Technical Analysis	—	66.67%	16.67%	53.76%
Macro	—	0%	0%	0.19%
Earnings	—	0%	0%	5.39%
Analysts	—	0%	5.56%	5.39%
Controversies	—	0%	5.56%	0.19%

Earnings· May 10

Rockwell Medical, Inc. ($RMTI) reported earnings on 5/10 after close, with the stock dropping 12% since the last earnings report.
$RMTI met estimates, with a reported loss of $0.13, matching consensus expectations.
The company beat EPS loss estimates by $0.01, with $RMTI hosting a Q1 earnings call on the same day.

Announcements· Sep 9

Rockwell Medical, Inc. ($RMTI) has announced a product purchase agreement with the leading at-home and acute care dialysis provider in the US.
The agreement is expected to provide a significant boost to Rockwell Medical's business, with the company's products set to be used by a major dialysis provider.
The agreement is a major development for Rockwell Medical, with the company's products poised to play a key role in the growing at-home and acute care dialysis market.

Technical Analysis· Jun 25

$RMTI is being watched for a possible short on a head and shoulders formation.
The chart for $RMTI is overextended and showing signs of a top, with a potential short entry at 17.5-18.
$RMTI has broken below its 9 EMA support and is showing signs of deaccumulation, with a potential long entry on a resistance breakout.

Generated by AI

Community

Of the messages about RMTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	13.95%	18.4%
Newcomers	100%	90.91%	86.05%	81.6%

Regulars· Mar 21

Rockwell Medical's Q4 earnings show adjusted EBITDA profitability and record net sales, gross profit, and gross margin for the full-year 2023.
The company's profitability on an adjusted EBITDA basis in Q4 2023 and record net sales, gross profit, and gross margin for the full-year 2023 are key achievements.
Rockwell Medical's Q4 2023 earnings report shows a non-GAAP EPS of $0.02 and revenue of $22.1M, which misses the estimate by $0.53M.

Newcomers· Jan 20

Rockwell Medical's preliminary full-year 2025 results show a 14% increase in revenue to $69.5M, with a 22% gross margin and a positive operating cash flow of $2.3M.
The company's Q4 sales exceeded estimates at approximately $18.6M, with a significant improvement in gross margin from the previous quarter.
Newcomers to the stock are optimistic about its future, with some setting targets at $1.50 and $1.70, and others believing the stock is in a solid moment, with a potential price surge.

Generated by AI

News

Minot Light’s Bullish Stance on Rockwell Medical (RMTI)

7d agoYahoo Finance

Rockwell Medical Inc (RMTI) (Q2 2026) Earnings Call Highlights: Revenue Up 11% and Cash Flow ...

Rockwell Medical Inc (RMTI) expands gross margins to 18% and reiterates full-year guidance amid strategic West Coast growth.

1mo agoYahoo! Finance Canada

Rockwell Medical, Inc. Q2 2026 Earnings Call Summary

Moby summary of Rockwell Medical, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Also Discussed

Investors talking about RMTI also mention

#	Name	Attention
1	Catalyst Pharmaceuticals Inc.CPRX	0%new
2	Acadia Pharmaceuticals Inc.ACAD	0%+0
3	Halozyme Therapeutics Inc.HALO	0%0
4	Omeros Corp.OMER	0%+0
5	Cytokinetics, IncorporatedCYTK	0.01%+0
6	Celldex Therapeutics IncCLDX	0%+0
7	Supernus Pharmaceuticals, Inc.SUPN	0%new
8	ABIO - ARCA biopharma, Inc.	——
9	DaVita Inc.DVA	0%new
10	ANAC - Arctos NorthStar Acquisition Corp.	——

Rockwell Medical Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Rockwell Medical Inc. is a healthcare company focused on developing, manufacturing, commercializing, and distributing hemodialysis products for dialysis providers worldwide. Its portfolio centers on liquid and dry acid and bicarbonate concentrates, along with related mixers and ancillary supplies used in dialysis treatment. The company serves outpatient dialysis centers, hospital-based facilities, skilled nursing settings, and home care environments, supporting the day-to-day delivery of kidney care. Rockwell Medical’s products are designed to help maintain the dialysis process by removing toxins and balancing electrolytes in patients with end-stage kidney disease. The company operates manufacturing and distribution capabilities that support customers in the United States and international markets, making it an important supplier within the renal care and dialysis supply chain. Headquartered in Wixom, Michigan, Rockwell Medical continues to focus on specialized products and services for the hemodialysis market.

Website

Location

30142 South Wixom road

Wixom, MI, 48393

United States

Social

What share of all stock conversation is about RMTI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Aug 13

Rockwell Medical, Inc. (RMTI) reported solid earnings, maintaining guidance for 2026 with $100 million+ revenue and 30% profit margins, with a new medical device opportunity in the works.
The company showed encouraging signs in its Q2 2026 earnings, with top-line growth, improved gross margins, and positive cash flow, but second-half execution remains critical.
RMTI's Q2 2026 results included a 11% increase in net sales to $17.8M, a 30% increase in gross profit to $3.2M, and a 18% gross margin, with the company reiterating its 2026 annual guidance.

Generated by AI

Sentiment

Of the messages about RMTI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +50	85.71% -14.29	93.29% +13.33
Bearish	0%	0% -50	14.29% +14.29	6.71% -13.33

Bullish· Jan 20

Rockwell Medical, Inc. (RMTI) reported preliminary Q4 revenue of $18.6M, beating estimates, with a gross margin of 22% and positive operating cash flow for the second time in 2025.
The company's financial report has led to a significant price surge, with some analysts predicting a 198.80% change from the last price of $1.26, with a target price of $3.75.
RMTI's turnaround is in full effect, with the stock experiencing a 45% premarket gain, and a high buzz around the stock, with potential for dynamic trading ahead.

Bearish· Nov 12

$RMTI is facing a significant revenue decline due to Davita's reduced purchases, which could drop by 31-38 million next year.
The company's gross profit margin is expected to decline by up to 20% year-over-year, which could negatively impact the stock price.
Rockwell Medical's new contracts and pricing increases may not be enough to offset the revenue decline, leading to a prolonged bearish trend.

Generated by AI

Topics

Of the messages about RMTI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	33.33%	72.22%	35.07%
Technical Analysis	—	66.67%	16.67%	53.76%
Macro	—	0%	0%	0.19%
Earnings	—	0%	0%	5.39%
Analysts	—	0%	5.56%	5.39%
Controversies	—	0%	5.56%	0.19%

Earnings· May 10

Rockwell Medical, Inc. ($RMTI) reported earnings on 5/10 after close, with the stock dropping 12% since the last earnings report.
$RMTI met estimates, with a reported loss of $0.13, matching consensus expectations.
The company beat EPS loss estimates by $0.01, with $RMTI hosting a Q1 earnings call on the same day.

Announcements· Sep 9

Rockwell Medical, Inc. ($RMTI) has announced a product purchase agreement with the leading at-home and acute care dialysis provider in the US.
The agreement is expected to provide a significant boost to Rockwell Medical's business, with the company's products set to be used by a major dialysis provider.
The agreement is a major development for Rockwell Medical, with the company's products poised to play a key role in the growing at-home and acute care dialysis market.

Technical Analysis· Jun 25

$RMTI is being watched for a possible short on a head and shoulders formation.
The chart for $RMTI is overextended and showing signs of a top, with a potential short entry at 17.5-18.
$RMTI has broken below its 9 EMA support and is showing signs of deaccumulation, with a potential long entry on a resistance breakout.

Generated by AI

Community

Of the messages about RMTI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	9.09%	13.95%	18.4%
Newcomers	100%	90.91%	86.05%	81.6%

Regulars· Mar 21

Rockwell Medical's Q4 earnings show adjusted EBITDA profitability and record net sales, gross profit, and gross margin for the full-year 2023.
The company's profitability on an adjusted EBITDA basis in Q4 2023 and record net sales, gross profit, and gross margin for the full-year 2023 are key achievements.
Rockwell Medical's Q4 2023 earnings report shows a non-GAAP EPS of $0.02 and revenue of $22.1M, which misses the estimate by $0.53M.

Newcomers· Jan 20

Rockwell Medical's preliminary full-year 2025 results show a 14% increase in revenue to $69.5M, with a 22% gross margin and a positive operating cash flow of $2.3M.
The company's Q4 sales exceeded estimates at approximately $18.6M, with a significant improvement in gross margin from the previous quarter.
Newcomers to the stock are optimistic about its future, with some setting targets at $1.50 and $1.70, and others believing the stock is in a solid moment, with a potential price surge.

Generated by AI

Rockwell Medical

Social

Aug 13

Bullish· Jan 20

Bearish· Nov 12

Earnings· May 10

Announcements· Sep 9

Technical Analysis· Jun 25

Regulars· Mar 21

Newcomers· Jan 20

Minot Light’s Bullish Stance on Rockwell Medical (RMTI)

Rockwell Medical Inc (RMTI) (Q2 2026) Earnings Call Highlights: Revenue Up 11% and Cash Flow ...

Rockwell Medical, Inc. Q2 2026 Earnings Call Summary

Rockwell Medical Q2 2026 slides: narrowing losses, targeting profitability

Rockwell Medical Q2 2026 slides: margin gains fuel profitability push

Earnings call transcript: Rockwell Medical Q2 2026 revenue rises 11%

Also Discussed

Rockwell Medical Inc.

Company Information

Location

Minot Light’s Bullish Stance on Rockwell Medical (RMTI)

Rockwell Medical Inc (RMTI) (Q2 2026) Earnings Call Highlights: Revenue Up 11% and Cash Flow ...

Rockwell Medical, Inc. Q2 2026 Earnings Call Summary

Rockwell Medical Q2 2026 slides: narrowing losses, targeting profitability

Rockwell Medical Q2 2026 slides: margin gains fuel profitability push

Earnings call transcript: Rockwell Medical Q2 2026 revenue rises 11%

Also Discussed

Social

Aug 13

Bullish· Jan 20

Bearish· Nov 12

Earnings· May 10

Announcements· Sep 9

Technical Analysis· Jun 25

Regulars· Mar 21

Newcomers· Jan 20